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Significance Statement 
Genetic engineering of transplant cells has significant clinical application in achieving 
combinatorial therapy (i.e. cell replacement and therapeutic biomolecule delivery). Multimodal 
magnetic nanoparticles (MNPs) offer a key translational platform to achieve this by providing 
safe and scalable alternatives to viruses, with unique advantages in non-invasive cell tracking 
and localization. To further increase MNP utility, we have developed state of the art 
magnetofection protocols (application of static/oscillating magnetic fields) to enhance MNP 
mediated transfection of neural stem cells (NSCs; a key cell transplant population). Crucially, 
magnetofection is both safe and effective for NSCs propagated by two clinically relevant 
formats (neurospheres/monolayers), thereby offering an attractive methodology for translation 




Neural stem cells (NSCs) have high translational potential in transplantation therapies for 
neural repair. Enhancement of their therapeutic capacity by genetic engineering is an important 
goal for regenerative neurology. Magnetic nanoparticles (MNPs) are major non-viral vectors for 
safe bioengineering of NSCs, offering critical translational benefits versus viral vectors (safety, 
scalability and ease of use). This unit describes protocols for production of suspension 
(neurosphere) and adherent (monolayer) murine NSC cultures. Genetic engineering of NSCs 
with MNPs and application of ‘magnetofection’ (applied magnetic fields)/‘multifection’ (repeat 
transfection) approaches to enhance gene delivery are described. Magnetofection of 
monolayer cultures achieves optimal transfection, but neurospheres offer key advantages for 
neural graft survival post-transplantation; a further protocol is presented which allows the 
advantageous features of each approach to be combined into a single procedure for 
transplantation. The adaptation of these protocols for other MNP preparations is considered, 
with emphasis on the evaluation of procedural safety. 
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INTRODUCTION 
Neural stem cells (NSCs), a major transplant population for neural cell therapies (Kim and de 
Vellis, 2009), are routinely cultured as suspension (three-dimensional) neurosphere and as 
adherent (two-dimensional) monolayer cultures; each culture system has its own merits and 
disadvantages with respect to cell replacement therapies (Conti and Cattaneo, 2010). However, 
both culture formats are amenable to non-viral mediated gene delivery using magnetic 
nanoparticles (MNPs) (Pickard et al., 2011; Adams et al., 2013; Pickard et al., 2015), as 
described in this unit. A protocol for the preparation of NSC cultures from murine brain is firstly 
described (Basic Protocol 1), involving their initial derivation as neurospheres and followed by 
their propagation as either neurosphere or monolayer cultures. This is accompanied by an 
ancillary protocol for the preparation of polyornithine/laminin-treated culture surfaces for the 
latter (Support Protocol 1).  
We then describe protocols for MNP-mediated gene delivery to NSCs. Notably this process can 
be enhanced by the application of high gradient static/oscillating magnetic fields—the so-called  
‘Magnetofection Technology’—and/or multifection (repeat transfection) (Pickard et al., 2011; 
Adams et al., 2013; Pickard et al., 2015). Magnetofection of monolayers yields the highest 
transfection efficiencies, and a protocol for this is first described (Basic Protocol 2). 
Magnetofection and multifection also enhance MNP-mediated gene delivery to neurospheres, 
which is next considered (Alternate Protocol 2). Neurospheres offer key advantages in terms of 
neural graft survival post-transplantation (Mothe et al., 2008); a final protocol (Support 
Protocol 2) is presented, involving the formation of neurospheres from magnetofected 
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monolayers, thereby allowing the advantageous features of each system to be combined into a 
single procedure for the transplantation of genetically modified NSCs. 
While we have focused here on MNP-mediated gene delivery to NSCs using a particular 
commercial formulation of transfection-grade MNPs, termed NeuroMag, these protocols and 
approaches can be readily adapted to other MNP formulations, including those with primary 
application in magnetolabelling (for non-invasive cell tracking by MRI, for example). Key 
considerations that need to be addressed when adapting the presented protocols are 
highlighted throughout the unit. Procedural safety is a primary concern when manipulating NSC 
transplant populations; ways in which this can be evaluated are discussed in the final section of 
the unit (Commentary: Critical Parameters/Troubleshooting).  
 
BASIC PROTOCOL 1 
PREPARATION OF NEURAL STEM CELL SUSPENSION AND MONOLAYER CULTURES 
The protocol here describes methods to establish and maintain both neurosphere and 
monolayer cultures of NSCs. Firstly, the subventricular zone (SVZ) is dissected from neonatal 
mouse cerebral cortex and cells are mechanically dissociated and sieved to obtain a single cell 
suspension. Cells are then seeded into low adherence culture flasks in culture media containing 
EGF and FGF to stimulate stem cell proliferation, resulting in the formation of neurospheres. 
This suspension culture system is a more convenient format to deal with the relatively high 
level of cell death (largely of non-NSCs) that occurs immediately after the initial establishment 
of cultures, and which would otherwise cause detachment of colonies in monolayer culture 
formats. Cell death normally resolves within the first 2 – 3 days of culture, resulting in the 
emergence of characteristic balls of cells or neurospheres. These are enzymatically dissociated 
at 7 days post-seeding, then reseeded either as neurosphere cultures for routine propagation 
of NSC stocks/transfection or as monolayer cultures for transfection. 
NOTE: All reagents/solutions and equipment (including that used for dissection) that comes into 
contact with tissue/cells must be sterile. 




Mice; CD1 strain; at 1 – 3 postnatal days 
Phosphate-buffered saline (PBS; 10 mM phosphate buffer, 2.7 mM potassium chloride and 137 
mM sodium chloride, pH 7.4) 
NS-M medium (see recipe) 
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DNase I (10x; see recipe) 
Accutase/DNase I (see recipe) 
Trypan blue (0.4%) 
Stereomicroscope or dissecting microscope 
Standard microscope 
Inverted microscope 
Dissection equipment: Watchmaker forceps (110 mm); scalpel blades no.10 
Kimberley Clark paper hand towels 
Universal tubes 
50 ml Falcon-type tubes 
Eppendorf tubes (1.5 ml) 
Neubauer counting chamber and coverslip 
Cell sieves (40 µm mesh size) 
Petri dishes; 10 cm and 3.5 cm diameter 
Manual pipettors 
Transfer pipettes 
Untreated Nunc T-25 flasks for suspension cultures (Thermofisher, code TKT-300-010J) 
Untreated Nunc 24-well plates for suspension cultures (Thermofisher, code TKT-220-024P) 
Cell culture treated Nunc 24-well plates for monolayer cultures (Thermofisher, code 142475) 
 
Dissection and culture preparation 
1. Euthanize mouse pups by a humane (Schedule 1) method. Aseptically dissect out the 
whole brain and transfer this to a Universal tube containing ice-cold PBS (ca. 5 
ml/brain).  
 
2. In a laminar flow cabinet, transfer the brains to a Petri dish (10 cm diameter), and 
replace PBS with fresh. Gently transfer each brain in turn to a fresh hand towel, and 




Use curved forceps to lift brains and avoid applying excessive pressure as early postnatal 
brain tissue has a relatively high water content and can be easily damaged. 
 
3. Using a scalpel, remove and discard olfactory bulbs plus a 1 mm band of forebrain tissue 
caudal to the bulbs. Collect a 2 – 3 mm band of tissue caudal to this cut, and carefully 
transfer this to individual Petri dishes (3.5 cm diameter) containing a small amount of 
PBS (ca. 3 ml) with the more caudal portion facing upwards.  
 
4. Under a stereo-microscope or dissecting microscope, bisect cortical tissue into its two 
halves and, using a fresh scalpel blade, carefully remove tissue surrounding the SVZ 
(Figure 1A). 
 
With each cut of the blade, push the extraneous tissue to the edge of the Petri dish, 
leaving only the two SVZs in the centre of the dish.  
 
5. Using a transfer pipette, transfer SVZs into an Eppendorf tube; remove any PBS carry-
over using a manual pipettor. 
 
6. Add NS-M (0.5 ml/pair of SVZs) followed by 0.1 volume of DNase I (10X). 
 
The DNase I will digest any DNA released from cells during the subsequent mechanical 
dissociation steps, which would otherwise cause cell clumping. 
 
7. Dissociate the tissue mechanically using a P1000 followed by a P200 manual pipettor. 
 
8. Centrifuge (1000 rpm, 5 min) to collect cells. Resuspend the pellet in fresh NS-M (ca. 1 
ml/brain) and pass this through a cell sieve (40 µm) into a 50 ml Falcon-type tube, 
followed by a further 1 ml NS-M wash through.  
 
9. Perform a viable cell count, and adjust the density of the main stock to 105 cells/ml by 
adding fresh NS-M. Add 4 - 5 ml of this per T25 flask and incubate.  
 
For the cell count, dilute a sample of cell suspension 1:1 with trypan blue solution (0.4%) 
and load the mix into a Neubauer chamber – non-viable cells take up the dye and appear 
blue, while viable cells exclude the dye and appear transparent. 
 
10. Observe cultures daily; discourage neurosphere adherence to plastic by regularly giving 
culture vessels a sharp tap. Feed cultures every 2 – 3 days by performing a 50% medium 
change.  
 
Use a ruler to give culture vessels a sharp tap laterally to dislodge any neurospheres 
which are attaching to the culture flask. There will be many dead or dying cells in the 
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first two days after establishing cultures. However, these and cell debris will start to 
clear after 2 - 3 days resulting in the emergence of balls of cells which will increase in size 
as cells proliferate over the ensuing days (Figure 1B). 
 
11. Cells should be passaged after 1 week (or when spheres reach ca. 150 µm in diameter). 
To do this, collect the neurospheres by centrifugation (1000 rpm, 5 min) of the entire 
flask contents and wash the pellet once with PBS. Then gently resuspend neurospheres 
in accutase/DNase I solution. After incubation for 10 min at 37 °C, mechanically 
dissociate the spheres, as per step 7, and centrifuge (1000 rpm, 5 min) to collect cells.  
 
12. For secondary neurosphere cultures, resuspend cells at a density of 105 cells/ml NS-M 
and re-plate in non-treated, polystyrene T25 flasks (4 – 5 ml/flask; for main stock) 
and/or 24-well plates (0.5 ml per well; for transfection), as desired. For monolayer 
cultures for transfection, resuspend cells at a density of 3 x 105 cells/ml ML-M and re-
plate (0.4 ml per well) in 24-well plates pre-treated with polyornithine-laminin (see 
Support Protocol 1). 
 
SUPPORT PROTOCOL 1 
COATING OF CULTURE SURFACES AND COVERSLIPS WITH POLYORNITHINE-LAMININ 
Coating of culture substrates promotes the adherence of NSCs in monolayer cultures and a 
mixture of polyornithine-laminin is normally used for this purpose, though other coatings are 
possible. For experiments involving a range of cellular microscopic analyses, it is convenient to 
place sterile acid-washed coverslips into wells of 24-well plates and to coat these in situ before 
seeding monolayer cultures. 
Materials 
PBS (Basic Protocol 1) 
Poly-ornithine (0.01% solution; Sigma-Aldrich P4957); diluted 1 in 5 in PBS just before use 
Laminin (1 mg/ml; Sigma-Aldrich code L-2020); stored as 25 µl aliquots at -20 °C; diluted 1 in 
200 in PBS just before use 
Coverslips (circular, 13 mm diameter); acid-washed before use and sterilised 
Cell culture treated Nunc 24-well plates (Thermofisher, code 142475) 
 
Coating procedure 
1. Add coverslips to wells, if required. 
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2. Add 0.25 ml diluted poly-ornithine per well and incubate at 37 °C for 1 h. 
3. Aspirate and wash wells x1 with 0.5 ml PBS. 
4. Add 0.25 ml diluted laminin per well. Incubate at 37 °C for 1 h. 
5. Aspirate and wash wells x3 with PBS (0.5 ml). 
Do not remove the final PBS wash until just before cell seeding to prevent the wells from drying 
out. 
 
BASIC PROTOCOL 2 
MAGNETOFECTION OF NSC MONOLAYER CULTURES 
Here protocols are described for the magnetofection of NSC transplant populations using a 
commercial transfection-grade MNP preparation, NeuroMag. These are iron oxide containing 
MNPs which carry a positive charge and for which the average particle size is 160 nm (range 
140 – 200 nm). When developing and optimizing these protocols, several commercial MNP 
preparations were tested and NeuroMag, which was originally developed for the transfection of 
neurons, consistently yielded the highest transfection efficiency with minimal toxicity, 
irrespective of the culture format. Note that to completely avoid toxicity, the concentration of 
NeuroMag used in the protocol is much lower than that recommended by the manufacturer for 
the transfection of neurons. The application of magnetic fields enhances gene delivery by this 
reagent, with oscillating magnetic fields outperforming static magnetic fields in both adherent 
and suspension culture formats. However higher transfection efficiencies are consistently 
obtained with monolayer versus neurosphere cultures and, for this reason, the main protocol in 
this section focusses on procedures for MNP-mediated gene delivery to NSC monolayers, while 




ML-M medium (as per recipe but minus antibiotics) 
DMEM: Ham’s F12 medium (1:1) 
Plasmid (0.5 µg/µl water; stored at -20 °C in aliquots; vortex before use)  




Magnefect-Nano oscillating magnetic array system (nanoTherics Ltd), with a 24-magnet array 
(NdFeB, grade N42; field strength of 421 ± 20 mT) 
 
Magnetofection of NSC monolayers 
1. After plating monolayers in 24-well plates (Basic Protocol 1, step 11), incubate overnight (18 - 
24 h) to allow cell attachment to the substratum. 
2. Replace medium with 0.225 ml fresh ML-M minus antibiotics. 
3. After 2 h, prepare transfection complexes. The following is per well; prepare multiples of this 
according to the number of wells required. Firstly, dilute 176 ng plasmid (i.e. 0.352 µl of a 0.5 
µg/µl stock) with 75 µl base medium (1:1 mix of DMEM:Ham’s F12 with no additions), and mix 
by vortexing. Secondly, add all of this to an Eppendorf tube containing 0.62 µl NeuroMag (or 
water for plasmid only controls). Carefully mix by pipetting up and down 10 times using a P1000 
manual pipettor. Incubate at room temperature for 20 min exactly. 
Dynamic light scattering approaches have shown that binding of plasmid (size 3.5 kb) by 
NeuroMag under the above conditions increases particle size by ca. 35% (Pickard and Chari, 
2010); extended incubations for complex formation result in marked aggregation of particle-
plasmid complexes and are to be avoided. A ratio of 3.5 µl NeuroMag/µg DNA is used here, at 
which particle binding of plasmid is maximal (Pickard and Chari, 2010).    
4. Add 75 µl complexes (or plasmid only controls) drop-wise to cells whilst gently swirling the 
plate. Immediately place the culture plate on the desired magnetic field in the incubator.  
Gently pipette complexes to avoid disrupting these. For optimal transfection efficiency, an 
oscillating magnetic field (of frequency 4 Hz and amplitude 0.2 mm) is recommended, yielding 
values that are more than treble those of basal (no magnetic field) conditions. If an oscillating 
magnetic field system is not available, then a static magnetic field can be used, but this will 
produce only a doubling of basal transfection efficiency.  
5. After 30 min, remove the plate from magnetic field. 
6. After a further 30 min, aspirate medium from cells and replace with 0.4 ml fresh ML-M 
(minus antibiotic). 
7. Culture cells as normal. 
As judged from experiments with plasmids encoding fluorescent reporter proteins or growth 
factors tagged with the latter, transgene expression is maximal at 48 h. If longer incubation 
times are required, then it will be necessary to maintain cultures (i.e., feeding every 48 h) and to 
passage these before they become confluent. 
8. Transfection can be increased by repeating steps 2-6, 24 h after the initial transfection. 
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Magneto-multifection in monolayers has been shown to increase transfection efficiency from ca. 
43 to 52% with a concomitant doubling in mean cell fluorescence intensity when introducing 
Green Fluorescent Protein (GFP) encoded by minicircles (plasmid DNA without the bacterial 
backbone) suggesting higher levels of expression compared to single transfections (Fernandes 
and Chari, 2016a). 
9. If required, neurospheres can be reformed from transfected monolayers, as detailed in 
Support Protocol 2.  
 
ALTERNATE PROTOCOL 2 
MAGNETOFECTION AND MULTIFECTION OF NSC SUSPENSION CULTURES  
MNPs can also be used to safely deliver genes to the widely studied neurosphere NSC culture 
model (Pickard et al., 2011; Adams et al., 2013). While this can also be enhanced by the 
application of magnetic fields (specifically oscillating magnetic fields), transfection efficiencies 
are lower than for NSC monolayers (Adams et al., 2013; Pickard et al., 2015). However, an 
alternative approach to enhance transfection, termed multifection, and involving the repeat 
administration of transfection complexes (Pickard et al., 2011), can be safely employed to attain 
efficiencies which exceed those obtained using oscillating magnetic fields (Adams et al., 2013). 
Here we describe protocols for the magnetofection and multifection of neurosphere cultures 
using NeuroMag MNPs.  
 
Materials 
NS-M medium (as per recipe but minus antibiotics) 
DMEM: Ham’s F12 medium (3:1) 
Plasmid (0.5 µg/µl water; stored at -20 °C in aliquots; vortex before use)  
NeuroMag transfection reagent (Oz Biosciences; stored at -20 °C in aliquots; 30 second vortex 
before use) 
Magnefect-Nano oscillating magnetic array system (nanoTherics Ltd), with a 24-magnet array 
(NdFeB, grade N42; field strength of 421 ± 20 mT) 
 
Transfection of neurospheres 
1. After plating of dissociated neurospheres in untreated 24-well plates (105 cells/ml NS-M; 0.5 
ml per well; Basic Protocol 1, step 11), culture overnight (20 – 24 h). 
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Transfections have been conducted at passages 2 – 4 without any appreciable loss in 
transfection efficiency. 
2. Prepare complexes. The following is per well; prepare multiples of this according to the 
number of wells required. Firstly, dilute 125 ng plasmid (i.e. 0.25 µl of a 0.5 µg/µl stock) with 50 
µl base medium (3:1 mix of DMEM:F12 with no additions), and mix by vortexing. Secondly, add 
all of this to an Eppendorf tube containing 0.435 µl NeuroMag (or water for plasmid only 
controls). Carefully mix by pipetting up and down 10 times using a P1000 manual pipettor. 
Incubate at room temperature for 20 min exactly. 
Note that neurosphere size influences the extent of transfection; extended culture of NSCs prior 
to transfection will result in larger sized neurospheres and reduced transfection efficiency 
(Pickard et al., 2011). NeuroMag exhibits dose-dependent toxicity in neurosphere cultures; the 
dose employed here is non-toxic (Pickard et al., 2011). Furthermore, the NeuroMag:DNA ratio of 
3.5 µl/µg used here is that at which particle binding of plasmid is maximal (Pickard and Chari, 
2010).    
3. Add 50 µl complex or control mix dropwise to neurospheres whilst gently swirling the plate 
and immediately return to the incubator. For magnetofection, incubate the plate with an 
oscillating magnetic field (of frequency 4 Hz and amplitude 0.2 mm) for the first 30 min. 
Gently pipette complexes to avoid disrupting these. Static magnetic fields have negligible effects 
on the transfection efficiency of NeuroMag in neurospheres. 
4. At 24 h after addition of complexes, a further transfection can be performed to safely 
enhance transfection efficiency, by simply repeating steps 2 and 3.  
Static magnetic fields also have negligible effects on the multifection of neurospheres with 
NeuroMag (Pickard et al., 2011; Adams et al., 2013). Magneto-multifection approaches 
employing oscillating magnetic fields have so far not been tested on NSC neurospheres. 
5. Culture cells as normal. 
Transgene expression will be maximal at 48 h after complex application i.e. 72 h post-plating for 
single transfections or 96 h post-plating for multifections. If longer incubation times are 
required, then it will be necessary to maintain cultures (i.e., feeding every 48 – 72 h) and to 
passage these before they become confluent. Periodic sharp tapping of culture vessels is 
recommended to prevent neurosphere adherence to culture surfaces. 
 
SUPPORT PROTOCOL 2 
FORMATION OF NEUROSPHERES FROM TRANSFECTED MONOLAYER CULTURES 
Magnetofection of NSC monolayer cultures yields higher transfection efficiency than that of 
NSC neurosphere cultures, but transplantation of neurospheres can yield better graft survival 
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than that of dissociated cells. Since magnetofected NSC monolayers can form neurospheres, 
even after transfection with a functional gene (FGF2) (Pickard et al., 2015), it is possible to 
combine the advantageous features of both systems using the protocol described here.   
 
Materials 
Magnetofected NSC monolayers (generated by Basic Protocol 2) 
PBS (as per Basic Protocol 1) 
Accutase/DNase I (see recipe) 
NS-M medium (see recipe) 
Trypan blue (0.4%) 
Neubauer counting chamber and coverslip 
Untreated Nunc T-25 flasks and/or Nunc 24-well plates for suspension cultures (Thermofisher, 




Formation of neurospheres from magnetofected monolayers 
1. Remove and discard medium from transfected monolayers, and carefully wash these once 
with PBS (0.5 ml well) so as not to disturb the monolayers. Discard this wash. 
2.  Add accutase/DNase I solution (0.5 ml/well) and incubate at 37 °C. Regularly observe wells 
microscopically, until cells start to detach from wells (ca. 5 min). 
Avoid overexposing cells to accutase-DNAse I solution; regularly observe wells on an inverted 
microscope during the dissociation process and collect the well contents as soon as cells start to 
detach. 
3. Immediately transfer the cell suspension to a centrifuge tube. Wash wells twice with 0.5 ml 
PBS per wash (to maximize cell collection) and combine washes with detached cells. 
4. Centrifuge (1000 rpm, 5 min) to collect cells.  
5. Resuspend cells at a density of 105 cells/ml NS-M and re-plate in non-treated, polystyrene 




REAGENTS AND SOLUTIONS 
Neurosphere medium (NS-M) 
A 3:1 mix of DMEM and Ham’s F12 (both media from Life Technologies) containing: 
2% B27 supplement (Life Technologies) 
20 ng/ml bFGF (see recipe) 
20 ng/ml EGF (see recipe) 
5 ng/ml Heparin (Sigma-Aldrich; prepared from a 5 µg/ml working solution in DMEM/Ham’s F12 [3:1]) 
1X Penicillin/streptomycin (added from 100x stock)   
Store at 4 °C for ≤1 week 
 
Monolayer medium (ML-M) 
A 1:1 mix of DMEM and Ham’s F12 (both media from Life Technologies) containing: 
1% N2 supplement (Life Technologies) 
20 ng/ml bFGF (see recipe) 
20 ng/ml EGF (see recipe) 
5 ng/ml Heparin (Sigma-Aldrich; prepared from a 5 µg/ml working solution in DMEM/Ham’s F12 [3:1]) 
1X Penicillin/streptomycin (added from 100x stock)   
Store at 4 °C for ≤1 week 
 
Human recombinant basic fibroblast growth factor (bFGF) 
Aseptically dissolve 25 µg bFGF (Sigma-Aldrich, product F-0291) in 0.625 ml sterile 20 mM Tris HCl, pH 7 
for a 40 µg/ml solution. Store aliquots at -80 °C. 
 
Human recombinant epidermal growth factor (EGF) 
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Aseptically dissolve 200 µg EGF (R&D Systems, product 236EG) in 5 ml sterile 10 mM acetic acid 
containing 0.1% BSA. Store aliquots at -80 °C. 
 
DNAse I  
Dissolve 100 mg DNAse I (Roche; product 1284932) in 20 ml DMEM/F12 (3:1) to make a 10x stock 
solution and store aliquots at -20 °C. 
 
Accutase/DNase I 





NSCs are capable of continuous self-renewal and can differentiate into the three major cell 
types of the central nervous system (CNS), namely neurons, astrocytes, and oligodendrocytes 
(Conti and Cattaneo, 2010). Furthermore, they exhibit low immunogenicity, are non-
tumorigenic, can migrate long distances in the CNS—especially towards pathological foci—and 
can enhance endogenous pro-regenerative activity (Meng et al., 2003; de Filippis, 2011). 
Consequently, they are a major transplant population for cell therapies to promote repair in 
neuropathological conditions. Their therapeutic capacity can be enhanced by genetic 
engineering; for example, to increase the delivery of regeneration-promoting molecules to sites 
of pathology (Phillips and Tang, 2012). Traditionally, this has been accomplished with viral 
vectors, which have several drawbacks, notably safety issues and scale-up limitations (Mintzer 
and Simanek, 2009; Elsabahy et al., 2011).  
In this context, nanomaterials, especially MNPs, are emerging as major non-viral gene delivery 
vectors for the safe bioengineering of NSCs. MNPs typically comprise magnetic cores 
overcoated with biocompatible materials that can be functionalized for the binding of a range 
of molecules, including nucleic acids (i.e. DNA plasmids, oligonucleotides and siRNA) (Plank et 
al., 2011; Yiu, 2011). Cellular internalisation of the resulting transfection complexes (and 
consequently gene delivery) is mediated via endocytotic uptake mechanisms; this step can be 
markedly enhanced by the application of static or oscillating magnetic fields (so called 
‘magnetofection’ or ‘magnet-assisted transfection’ approaches), which can enhance particle 
interaction with the cellular endocytotic machinery. Notably, amongst conventional viral and 
non-viral vector-based genetic modification approaches, MNPs uniquely can offer a 
combination of key benefits for experimental and clinical cell therapies, especially: i. non-
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invasive tracking of transplanted cells in vivo (since MNPs are routinely used as MRI contrast 
agents (Berman et al., 2011)); and ii. magnetic cell localization strategies (i.e. the application of 
magnetic fields over sites of pathology to localize systemically administered transplant cells 
(Polyak et al., 2008; Carenza et al., 2014)). 
Two culture systems are routinely used for the propagation of NSCs i.e., neurosphere (three-
dimensional; suspension) and monolayer (two-dimensional; adherent) cultures; each has 
distinct features (Conti and Cattaneo, 2010). Relative to monolayer cultures, neurospheres yield 
a high density of cells within a small culture surface area; an important consideration for clinical 
translation, which often requires large numbers of cells. Furthermore, the transplantation of 
neurospheres as opposed to dissociated cells is thought to be more beneficial for graft survival 
(Mothe et al., 2008). On the other hand, neurosphere cultures yield a more heterogeneous 
population of cells than monolayer cultures, with a tendency towards the presence of 
differentiated cells within the neurosphere core (Jensen and Parmar, 2006). Although cells in 
neurosphere cultures retain multipotentiality with progressive subculture, neurogenic potential 
tends to decline relative to gliogenic potential (Conti and Cattaneo, 2010). In contrast, cells in 
monolayer cultures exhibit more homogeneous behaviours and generally retain their 
neurogenic potential even upon prolonged passage (Conti and Cattaneo, 2010). The latter can 
be a key consideration for cell therapies for which the intended purpose is the replacement of 
damaged neurons. Both systems are amenable to MNP-mediated gene delivery, which can be 
increased by several approaches, including multifection (as demonstrated for neurospheres) 
(Pickard et al., 2011) and magnetofection, especially employing an oscillating magnetic field (as 
demonstrated for both neurospheres and monolayers) (Adams et al., 2013; Pickard et al., 
2015). Overall, the highest levels of transfection are obtained using monolayer NSCs and 
magnetofection. Magnetofected monolayer NSCs can, in turn, reform neurospheres, allowing 
the advantages of this system in terms of transplant survival to be exploited.    
 
Critical Parameters and Troubleshooting 
Critical reagent and protocol parameters 
These protocols were devised for the genetic engineering of NSC transplant populations with 
clinical translation in mind, and as an alternative to widely used viral transduction and other 
non-viral methods (i.e., electroporation and lipofection-based approaches). Safety was 
therefore of primary concern when developing these methods, and the MNP doses used and 
exposure times to NeuroMag/magnetic fields have been carefully optimized to minimize 
cytotoxicity. It is recommended that the NeuroMag particles are aliquoted upon receipt, to 
avoid excessive freeze-thawing, and that only endotoxin-free preparations of pure plasmid are 
used; the concentration of the latter should be carefully verified for each preparation. The 
formation of MNP-plasmid complexes is a critical step to determining a successful outcome. It is 
important to mix reagents in serum-free medium (serum inhibits complex formation), to allow 
complexes to form for only the specified time (to prevent time-dependent aggregation) and to 
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carefully pipette complexes (to avoid their disruption). Complex formation will therefore need 
to be carefully staggered when performing magnetofection of multiple plates on a single 
device. Excessive sequential use of the Magnefect-Nano at high frequencies and/or for 
prolonged periods of time may increase the temperature within tissue culture plates (at least 
for the original model of the device) and this can be periodically checked using a mock culture 
with determination of media temperature. 
 
Determining optimal plasmid:DNA ratios and plasmid vectors 
Maximal DNA binding capacity of MNPs can be determined by conducting a DNA binding curve. 
This is achieved by complexing a constant amount of DNA to various amounts of particles as in 
Basic Protocol 2. After the 20 minute incubation, centrifuge the Eppendorf to remove 
complexes. Free DNA can then be assessed by absorbance at 260 nm and presented as a 
percentage of a no particle control (Pickard and Chari, 2010). The ratio of NeuroMag: plasmid 
used here (i.e. 3.5 µl/µg) is equivalent to the maximal DNA binding capacity of the MNPs; 
consequently, increasing the amount of plasmid will have no beneficial effect on transfection, 
while reducing the amount of plasmid will lower transfection efficiencies. For similar reasons, 
alterations in plasmid size will also affect transfection efficiency, due to variation in plasmid 
copy number complexed with MNPs; increasing plasmid size will decrease—and decreasing 
plasmid size will increase—transfection efficiency (Pickard et al., 2015). For functional gene 
delivery in particular, it is recommended that insert size and/or extraneous plasmid sequences 
are kept to the minimum required to achieve the desired experimental goal. Strong evidence 
suggests that the use of minicircle vector systems may be beneficial in this regard. These 
vectors are further suited to translation as they contain no bacterial backbone elements (e.g. 
antibiotic resistance genes and origin of replication) meaning they are safer than conventional 
plasmids but also demonstrate sustained gene expression due to reduction of mammalian 
transgene silencing mechanisms (Fernandes and Chari, 2016a). Minicircle DNA encoding brain-
derived neurotrophic factor has been successfully delivered to NSCs using magnetofection 
technology, with functional in vitro effects observed from secreted BDNF, including enhanced 
NSC proliferation and differentiation into neurons (Fernandes and Chari, 2016b). 
 
Application of protocols to other transfection grade particles: Initial optimization and 
subsequent safety analyses 
When transferring these protocols to other preparations of transfection-grade MNPs (or MNPs 
intended for applications other than gene transfer), it will be important to carefully optimize a 
number of parameters. Optimal DNA binding should be determined as above. The MNP 
concentration used together with the duration of exposure of particles to cells are of prime 
importance, if toxicity is to be minimized. Such preliminary experiments should be conducted 
using a range of MNP concentrations complexed with the nucleic acid of choice, since this 
addition can influence surface charge of the particles and consequently, their cellular uptake 
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and gene delivery potential. Furthermore, it is judicious to include cells exposed to a magnetic 
field (static at least), since the latter influences particle interaction with cells and consequently, 
cytotoxicity. Initial screening can then be conveniently performed by phase-contrast 
microscopic observation of treated and control (no particle) cultures; cytotoxicity will be 
evident by the rounding and detachment of NSCs in monolayer cultures and by friable 
appearing spheres with dead/dying cells in neurosphere cultures, which are also of smaller size 
than control suspension cultures (Figure 2).  
Qualitative assessment of NSC health can then be supplemented with quantitative measures of 
cell number/cell viability post-harvesting of cells/neurospheres. Cells from both culture systems 
can be re-plated on polyornithine/laminin-coated coverslips and either cultured in ML-M for 
staining with antibodies to SOX2 and nestin by immunocytochemistry to assess stem cell state 
or cultured in differentiation medium (i.e. ML-M minus growth factors but supplemented with 
1% fetal bovine serum) for staining with antibodies to β-tubulin III (neuronal marker), glial 
fibrillary acidic protein (astrocytic marker) and myelin basic protein (oligodendrocytic marker) 
to assess differentiation potential, as detailed elsewhere (Pickard et al.,  2011; Adams et al., 
2013; Pickard et al., 2015). It is important to note that we primarily use a microscopic based 
approach to assess both transfection efficiency, cellular morphology and staining profiles 
simultaneously. This enables data generation with respect to multiple safety readouts 
(including cell morphology, numbers of cells, staining profile, proportions of stem or daughter 
cells and pyknotic nuclei) to be performed on the exactly the same cells that are used for 
transfection analysis.  
 
Anticipated Results 
Using plasmids that encode fluorescent proteins, transgene expression is usually evident by 
approximately 6 hours post-complex application and increases over time to become maximal by 
approximately 40 – 48 h (Figure 3). To assess transfection efficiency we use a microscopic based 
approach which allows for simultaneous safety and transfection analyses on the same samples. 
This is routinely performed using fixed monolayers although it can also be achieved using 
dissociated cells from neurospheres. The protocols described here are for transient gene 
expression; in the longer term, transgene expression declines but is usually observable up to 14 
days post-transfection. Typical transfection efficiencies for a 3.5 kb plasmid encoding GFP in the 
various protocols are summarized in Table 1; the transfection efficiencies obtained are usually 
highly reproducible under the conditions specified here. While transfection efficiencies are 
lower for larger plasmids, functionally relevant levels of expression of FGF2 (plasmid size 7.5 kb) 
(Pickard et al., 2015) and BDNF (minicircle size 4.1 kb) (Fernandes and Chari, 2016b) have been 
observed in bioassays. It should be noted that whilst MNP-mediated transfection does not 
affect NSC differentiation potential, irrespective of the culture system under study (Pickard et 
al., 2011; Adams et al., 2013), transgene expression is largely confined to astrocytic progeny for 





Preparation of the initial neurosphere culture takes approximately 2 – 3 hours, depending on 
the numbers of dissections to be performed, and these need to be cultured for one passage 
(usually one week) before MNP-mediated gene delivery can be attempted. Secondary 
neurosphere and monolayer cultures for transfection can be established within 60 - 90 min, but 
it is important to start the coating of monolayer culture surfaces beforehand, as this will take 
approximately 2.5 hours. Irrespective of the culture format, cells need to be cultured for 18 – 
24 h prior to transfection. Magnetofection of monolayer cultures usually takes approximately 
3.5 h from start to finish for a single plate/magnetic field condition; when applying a range of 
magnetic field conditions, then the whole process can be staggered at 30 min intervals. The 
procedure time for magnetofection of neurosphere cultures is shorter at around 90 min per 
plate, however for multifection the procedure will need to be repeated on two consecutive 
days. Allow a further 48 h after the final application of complexes to cells for maximal gene 
expression. The procedure for the formation of neurospheres from monolayer cultures takes 
approximately 1 h and, if required, this can be performed at 24 h (rather than at 48 h) post-
complex addition with no adverse effects. If assessing differentiation potential of transfected 
NSCs, cells are normally detached/dissociated 48 h after transfection then cultured in 
differentiation medium for 1 week. 
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KEY REFERENCE (optional) 
INTERNET RESOURCES (optional) 
FIGURE LEGENDS 
Figure 1. SVZ dissection and NSC culture as neurospheres. (A) Schematic of SVZ location in a 
coronal brain slice highlighted by red boxes alongside representative light microscope image of 
coronal slice with SVZ appearing as lighter region in the centre (yellow box and arrow). (B) 
Representative phase image of NSC cultures five days post SVZ dissociation. (B, inset) 
Representative phase image of NSCs starting to form neurospheres (arrows) two days post SVZ 
dissociation. Note the presence of debris from dead and dying cells, mostly non-NSCs, absent 
from the older cultures. 
Figure 2. Microscopic detection of MNP mediated toxicity in live cultures. (A) Representative 
phase image of NeuroMag toxicity in neurosphere cultures which is evident by friable 
neurospheres which also appear smaller than controls (depicted in the inset). (B) 
Representative phase image of toxicity in NSC monolayers with high numbers of rounded and 
detached cells compared to controls (depicted in inset). Images in A reproduced from Pickard et 
al. (2011), with permission, and in B (inset) from Pickard et al. (2015). 
Figure 3. MNP mediated transfection of NSCs in monolayers and neurospheres. (A-B) 
Representative fluorescent images of NSC monolayers transfected using NeuroMag under (A) 
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No field and (B) a 4 Hz oscillating magnetic field with increased numbers of cells expressing the 
reported protein, GFP. (C) Phase and (D) counterpart fluorescence image depicting 
neurospheres reformed from NSCs transfected under the 4 Hz oscillating field condition. (E-F) 
Representative fluorescent images of NSC neurospheres transfected with NeuroMag using (E) 
single transfection and (F) multifection which results in a higher number of GFP expressing cells. 
(E-F, insets) Counterpart phase images to the main images. Images in A – D, reproduced from 
Pickard et al., 2015; images in E & F reproduced from Pickard et al. (2011), with permission.  
Figure 4. Magnetofected cells can differentiate into their daughter cells. Representative triple 
merged images of NSCs transfected as neurospheres under a 4 Hz oscillating magnetic field 
which differentiate into (A) astrocytes, (B) neurons and (C) oligodendrocytes. Note that the 
majority of daughter cells expressing the transgene GFP are astrocytes with GFP expressing, 
GFAP positive astrocytes in (A) and GFP expressing cells with the morphological appearance of 











System n Transfection (% cells) Total cell no. (105) % Viability 
Neurospheres/multifection     
Day 1 8 13.7  ± 1.8 1.49 ± 0.20 97.6 ± 0.5 
Days 1 + 2 8 22.6 ± 2.4 1.59 ± 0.20 96.2 ± 1.4 
Monolayers/magnetofection     
No field 4   9.4  ± 1.0 2.42 ± 0.27 96.3 ± 0.3 
Static field 4 18.4  ± 1.3 2.39 ± 0.44 95.7 ± 0.7 
Oscillating (4 Hz) field 4 32.2  ± 1.5 2.37 ± 0.41 95.9 ± 1.0 
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Table 1. Expected transfection efficiencies, cell number and culture viability for NeuroMag-
mediated multifection of neurospheres and magnetofection of monolayers. Data are from 
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